9 completed. 8 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 8 |
| Phase 2 | 1 | Completed 1 |
Follow CKD-519: new trials by email Literature Review of CKD-519 trials Research Report on CKD-519
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Drug Interaction Between CKD-519 and Rosuvastatin in Healthy Male Subjects Rosuvastatin 20 mg, CKD-519 200 mg, Rosuvastatin 20 mg & CKD-519 200 mg - Dyslipidemias | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 30 | 2017-05-08 | 2017-07-07 |
| To Assess the Safety, Efficacy and Tolerability of CKD-519, Administered With HMG-CoA Reductase Inhibitors Atorvastatin 20mg, Atorvastatin 20 mg + CKD-519 50 mg, Atorvastatin 20 mg + CKD-519 100 mg - Dyslipidemias | Phase 2 | Completed | Chong Kun Dang Pharmaceutical | 62 | 2017-03-23 | 2018-11-06 |
| Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519 CKD-519, Placebo - Dyslipidemia | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 18 | 2017-03-07 | 2017-07-07 |
| Study to Investigate the Effects of Food on the Pharmacokinetics/Pharmacodynamics of CKD-519 CKD-519 100mg, CKD-519 200mg - Healthy Volunteers | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 48 | 2016-08-01 | 2017-02-23 |
| Study to Investigate the Influence of CKD-519 on 24-h Ambulatory Blood Pressure in Healthy Adult Volunteers CKD-519 200mg, Placebo - Healthy Volunteers | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 32 | 2016-08-01 | 2017-02-23 |
| Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519 CKD-519, placebo - Dyslipidemia | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 24 | 2016-04-01 | 2017-07-13 |
| Study to Assess PK/PD Character, Safety/Tolerability of CKD-519 New Formulation in Healthy Male Subject. CKD-519 50mg 2Tabs., CKD-519 100mg 1Tab., CKD-519 100mg 1Cap. - Dyslipidemia | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 30 | 2015-10-01 | 2016-01-20 |
| Study to Investigate the Effect of Food on the Pharmacokinetics/Pharmacodynamics and Safety of CKD-519(CKD-519 FDI) CKD-519 200mg / Fasting, Standard Meal, High Fat Meal - Dyslipidemia | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 45 | 2015-06-01 | 2015-12-07 |
| Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519 CKD-519, placebo - Dyslipidemia | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 41 | 2014-06-01 | 2015-09-11 |
Dyslipidemias (9) · Hyperlipidemias (1)
Chong Kun Dang Pharmaceutical (9)
South Korea (8) · Australia (1)
Min-Su Park, Ph.D (2) · Ji Young Kim, MD, PhD (1) · Ji Young Park, MD, PhD (1) · Kyung-Mi Park, PhD (1) · Min Soo Park, MD, PhD (1)